首页 > 最新文献

European review for medical and pharmacological sciences最新文献

英文 中文
Predictive factors for lack of neurological improvement in acute stroke patients without large vessel occlusion treated with low-dose thrombolysis and screened with 3T MRI. 接受低剂量溶栓治疗并通过 3T 磁共振成像筛查的无大血管闭塞的急性中风患者神经功能无改善的预测因素。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_36975
S Q Huynh, C C Tran, T T H Nguyen, H M Le, B T Nguyen, T M Ngo, T M Le, D M Nguyen

Objective: The study evaluated the lack of neurological improvement and the factors influencing it in patients with acute ischemic stroke (AIS) without major arterial occlusion.

Patients and methods: A cross-sectional study was conducted on patients diagnosed with acute ischemic stroke without significant occlusion of major arteries, with imaging evidence from 3-tesla magnetic resonance imaging (MRI) scans at the S.I.S Hospital in Can Tho, Vietnam, from 2019 to 2023. Eligible patients received treatment with low-dose alteplase (a single dose of 0.6 mg/kg).

Results: Among the 268 patients included in the study, a significant improvement in neurological function was observed in 195 patients (72.8%) [modified Rankin Scale (mRS): 0-1 points], while 73 patients (27.2%) demonstrated little or no improvement after 3 months of treatment. There were no recorded fatalities during the study period. Female patients accounted for 35.8% of the total sample. The average age of the participants was 62.9 years. The multivariate regression analysis identified several predictive factors associated with the risk of lack of improvement after 3 months, including advanced age, higher National Institute of Health Stroke Scale (NIHSS) scores, elevated blood glycemia levels (mmol/L), and elevated high-sensitive (hs) troponin I levels (ng/mL) (p < 0.05). Glycemia and hs troponin I levels were identified as biomarkers for predicting outcomes after ischemic stroke. No evidence was found linking sex, a history of chronic illness, and a lack of improvement.

Conclusions: Predicting prognostic factors for lack of neurological improvement will assist neurologists in developing personalized treatment plans for patients, reducing complications, and promoting patient recovery.

研究目的本研究评估了无主要动脉闭塞的急性缺血性卒中(AIS)患者神经功能无改善的情况及其影响因素:这项横断面研究的对象是2019年至2023年期间在越南芹苴市S.I.S医院确诊为急性缺血性中风且无主要动脉明显闭塞的患者,其影像学证据来自3特斯拉磁共振成像(MRI)扫描。符合条件的患者接受低剂量阿替普酶治疗(单次剂量为 0.6 毫克/千克):在参与研究的 268 名患者中,195 名患者(72.8%)的神经功能明显改善[修改后的 Rankin 量表(mRS):0-1 分],而 73 名患者(27.2%)在治疗 3 个月后几乎没有改善。研究期间没有死亡记录。女性患者占样本总数的 35.8%。参与者的平均年龄为 62.9 岁。多变量回归分析确定了几个与 3 个月后病情无改善风险相关的预测因素,包括高龄、美国国立卫生研究院卒中量表(NIHSS)评分较高、血糖水平(mmol/L)升高和高敏(hs)肌钙蛋白 I 水平(ng/mL)升高(p < 0.05)。血糖和高敏感肌钙蛋白 I 水平被确定为预测缺血性中风后预后的生物标志物。没有证据表明性别、慢性病史与病情无改善有关:预测神经功能无改善的预后因素将有助于神经科医生为患者制定个性化治疗方案、减少并发症并促进患者康复。
{"title":"Predictive factors for lack of neurological improvement in acute stroke patients without large vessel occlusion treated with low-dose thrombolysis and screened with 3T MRI.","authors":"S Q Huynh, C C Tran, T T H Nguyen, H M Le, B T Nguyen, T M Ngo, T M Le, D M Nguyen","doi":"10.26355/eurrev_202412_36975","DOIUrl":"https://doi.org/10.26355/eurrev_202412_36975","url":null,"abstract":"<p><strong>Objective: </strong>The study evaluated the lack of neurological improvement and the factors influencing it in patients with acute ischemic stroke (AIS) without major arterial occlusion.</p><p><strong>Patients and methods: </strong>A cross-sectional study was conducted on patients diagnosed with acute ischemic stroke without significant occlusion of major arteries, with imaging evidence from 3-tesla magnetic resonance imaging (MRI) scans at the S.I.S Hospital in Can Tho, Vietnam, from 2019 to 2023. Eligible patients received treatment with low-dose alteplase (a single dose of 0.6 mg/kg).</p><p><strong>Results: </strong>Among the 268 patients included in the study, a significant improvement in neurological function was observed in 195 patients (72.8%) [modified Rankin Scale (mRS): 0-1 points], while 73 patients (27.2%) demonstrated little or no improvement after 3 months of treatment. There were no recorded fatalities during the study period. Female patients accounted for 35.8% of the total sample. The average age of the participants was 62.9 years. The multivariate regression analysis identified several predictive factors associated with the risk of lack of improvement after 3 months, including advanced age, higher National Institute of Health Stroke Scale (NIHSS) scores, elevated blood glycemia levels (mmol/L), and elevated high-sensitive (hs) troponin I levels (ng/mL) (p < 0.05). Glycemia and hs troponin I levels were identified as biomarkers for predicting outcomes after ischemic stroke. No evidence was found linking sex, a history of chronic illness, and a lack of improvement.</p><p><strong>Conclusions: </strong>Predicting prognostic factors for lack of neurological improvement will assist neurologists in developing personalized treatment plans for patients, reducing complications, and promoting patient recovery.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4646-4655"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A monoamine oxidase B inhibitor altered gene expression of catalytically active dual-specificity phosphatases in human oral gingival keratinocytes. 单胺氧化酶B抑制剂改变了人口腔牙龈角质形成细胞中催化活性双特异性磷酸酶的基因表达。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_37002
M Ostadkarampour, E E Putnins

Objective: Monoamine oxidase (MAO) inhibitors reduce inflammation in a number of in vitro and in vivo models. This finding led to the development of a novel MAO-B selective inhibitor (RG0216) designed to reduce blood-brain barrier penetration. To elucidate RG0216's regulatory role in inflammation-relevant signaling pathways, we employed a transcriptome analytic approach to identify genes that are differentially regulated by RG0216 and then globally identified which inflammation-relevant biological signaling pathways were altered by this drug.

Material and methods: Primary human gingival keratinocyte (HGK) cells were treated with RG0216, and RNA was extracted (4 h). RNAseq transcriptome analysis was utilized to identify differentially expressed genes (DEGs), while Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to identify significantly enriched biological pathways. Relevant genes associated with these pathways and RG0216 regulation of Porphyromonnas gingivalis lipopolysaccharide (PgLPS)-induced cytokine/chemokine expression were evaluated using the real-time quantitative reverse-transcription polymerase chain reaction (RT-qPCR) approach.

Results: RG0216 significantly altered the expression of 50 DEGs in HGK cells. Using GO and KEGG analytic approaches, these genes were associated with the biological pathways relevant to mitogen-activated protein kinase (MAPK) and MAPK phosphatases. These phosphatases are part of the 10-member catalytically active dual-specificity phosphatase (DUSP) family. RG0216 induced the expression of DUSP10, reduced the expression of DUSP4 and DUSP6, and decreased IL-6 and IL-8 expression in control and PgLPS-stimulated cultures.

Conclusions: In HGK cells, a novel MAO-B inhibitor (RG0216) significantly altered DUSP4, DUSP6, and DUSP10 expression. DUSPs play a regulatory role in MAPK activity and, therefore, can alter cellular inflammatory responses. We found that RG0216 inhibited IL-6 and IL-8 expression. Further studies are planned to examine RG0216's regulatory role in DUSP expression and its impact on the regulation of cytokine/chemokine expression.

目的:单胺氧化酶(MAO)抑制剂在许多体外和体内模型中减轻炎症。这一发现导致了一种新的MAO-B选择性抑制剂(RG0216)的开发,旨在降低血脑屏障的渗透。为了阐明RG0216在炎症相关信号通路中的调节作用,我们采用转录组分析方法鉴定受RG0216差异调节的基因,然后在全球范围内鉴定出哪些炎症相关的生物信号通路被该药物改变。材料和方法:用RG0216处理原代人牙龈角质形成细胞(HGK)细胞,提取RNA (4 h)。利用RNAseq转录组分析鉴定差异表达基因(DEGs),利用基因本体(GO)和京都基因与基因组百科全书(KEGG)分析鉴定显著富集的生物通路。采用实时定量逆转录聚合酶链反应(RT-qPCR)方法评估与这些途径相关的相关基因和RG0216调控牙龈卟啉单胞菌脂多糖(PgLPS)诱导的细胞因子/趋化因子表达。结果:RG0216显著改变HGK细胞50 DEGs的表达。使用GO和KEGG分析方法,这些基因与丝裂原活化蛋白激酶(MAPK)和MAPK磷酸酶相关的生物学途径相关。这些磷酸酶是10成员催化活性双特异性磷酸酶(DUSP)家族的一部分。RG0216诱导DUSP10的表达,降低DUSP4和DUSP6的表达,降低IL-6和IL-8在对照和pglps刺激培养中的表达。结论:在HGK细胞中,一种新的MAO-B抑制剂(RG0216)显著改变了DUSP4、DUSP6和DUSP10的表达。dusp在MAPK活性中起调节作用,因此可以改变细胞炎症反应。我们发现RG0216抑制IL-6和IL-8的表达。我们计划进一步研究RG0216对DUSP表达的调控作用及其对细胞因子/趋化因子表达的调控作用。
{"title":"A monoamine oxidase B inhibitor altered gene expression of catalytically active dual-specificity phosphatases in human oral gingival keratinocytes.","authors":"M Ostadkarampour, E E Putnins","doi":"10.26355/eurrev_202412_37002","DOIUrl":"https://doi.org/10.26355/eurrev_202412_37002","url":null,"abstract":"<p><strong>Objective: </strong>Monoamine oxidase (MAO) inhibitors reduce inflammation in a number of in vitro and in vivo models. This finding led to the development of a novel MAO-B selective inhibitor (RG0216) designed to reduce blood-brain barrier penetration. To elucidate RG0216's regulatory role in inflammation-relevant signaling pathways, we employed a transcriptome analytic approach to identify genes that are differentially regulated by RG0216 and then globally identified which inflammation-relevant biological signaling pathways were altered by this drug.</p><p><strong>Material and methods: </strong>Primary human gingival keratinocyte (HGK) cells were treated with RG0216, and RNA was extracted (4 h). RNAseq transcriptome analysis was utilized to identify differentially expressed genes (DEGs), while Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to identify significantly enriched biological pathways. Relevant genes associated with these pathways and RG0216 regulation of Porphyromonnas gingivalis lipopolysaccharide (PgLPS)-induced cytokine/chemokine expression were evaluated using the real-time quantitative reverse-transcription polymerase chain reaction (RT-qPCR) approach.</p><p><strong>Results: </strong>RG0216 significantly altered the expression of 50 DEGs in HGK cells. Using GO and KEGG analytic approaches, these genes were associated with the biological pathways relevant to mitogen-activated protein kinase (MAPK) and MAPK phosphatases. These phosphatases are part of the 10-member catalytically active dual-specificity phosphatase (DUSP) family. RG0216 induced the expression of DUSP10, reduced the expression of DUSP4 and DUSP6, and decreased IL-6 and IL-8 expression in control and PgLPS-stimulated cultures.</p><p><strong>Conclusions: </strong>In HGK cells, a novel MAO-B inhibitor (RG0216) significantly altered DUSP4, DUSP6, and DUSP10 expression. DUSPs play a regulatory role in MAPK activity and, therefore, can alter cellular inflammatory responses. We found that RG0216 inhibited IL-6 and IL-8 expression. Further studies are planned to examine RG0216's regulatory role in DUSP expression and its impact on the regulation of cytokine/chemokine expression.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 24","pages":"4681-4690"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smoking-related complications in foot and ankle surgery: a systematic review. 足部和踝关节手术中吸烟相关并发症:一项系统综述。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_37003
S Pour Jafar, R Garibaldi, A Seidel, S Soares

Objective: The detrimental effects of cigarette smoking on overall health are well-documented, with nicotine and carbon monoxide contributing to peripheral vasoconstriction and impaired oxygen delivery to tissues. This study reviews the impact of smoking on wound and bone healing, specifically in foot and ankle surgery, given its significant role as a modifiable risk factor for complications in orthopedic procedures.

Materials and methods: A systematic literature review was conducted in May 2024 following PRISMA guidelines. An electronic search of PubMed was performed using keywords related to smoking and wound complications in foot and ankle surgery. Inclusion criteria were studies published in English from 1993 to May 2024 focusing on orthopedic procedures. After screening 28 studies, six relevant articles were selected, comprising literature reviews, retrospective studies, and comparative series.

Results: The review highlights that smoking, including smokeless tobacco, significantly increases the risk of complications in foot and ankle surgeries. Smokers show markedly higher rates of non-union, wound infections, and delayed bone healing compared to non-smokers. For instance, smokers exhibit a 14.8% wound infection rate and higher rates of malunion and non-union, with 14.5% vs. 6.7% in non-smokers. Elective procedures such as total ankle replacement (TAR) also show worse outcomes for smokers, including increased infection rates and poorer functional scores. Conversely, smoking's impact on amputation procedures is less pronounced, although complications remain significant in patients with comorbid conditions.

Conclusions: This review underscores the severe impact of smoking on surgical outcomes in foot and ankle procedures. Smoking cessation before surgery has demonstrated substantial benefits, including reduced infection rates and improved healing. Preoperative counseling and smoking cessation programs are crucial for optimizing patient outcomes, and a multidisciplinary approach should be considered to enhance therapeutic strategies. Future studies should focus on refining smoking cessation guidelines and exploring new tobacco alternatives.

目的:吸烟对整体健康的有害影响是有据可查的,尼古丁和一氧化碳会导致周围血管收缩和组织氧气输送受损。本研究回顾了吸烟对伤口和骨愈合的影响,特别是在足部和踝关节手术中,吸烟是骨科手术并发症的一个可改变的危险因素。材料和方法:根据PRISMA指南,于2024年5月进行了系统的文献综述。使用与吸烟和足部和踝关节手术伤口并发症相关的关键词对PubMed进行电子搜索。纳入标准是1993年至2024年5月以英文发表的关于骨科手术的研究。在筛选28项研究后,选择6篇相关文章,包括文献综述、回顾性研究和比较系列。结果:该综述强调,吸烟,包括无烟烟草,显著增加足部和踝关节手术并发症的风险。与不吸烟者相比,吸烟者的骨不愈合、伤口感染和骨愈合延迟的发生率明显更高。例如,吸烟者的伤口感染率为14.8%,不愈合和不愈合的发生率更高,而不吸烟者为14.5%,而不吸烟者为6.7%。选择性手术如全踝关节置换术(TAR)对吸烟者也显示出更差的结果,包括感染率增加和功能评分较差。相反,吸烟对截肢手术的影响不太明显,尽管在有合并症的患者中并发症仍然很严重。结论:本综述强调了吸烟对足部和踝关节手术结果的严重影响。手术前戒烟已经证明了巨大的好处,包括降低感染率和改善愈合。术前咨询和戒烟计划对优化患者预后至关重要,应考虑多学科方法来加强治疗策略。未来的研究应侧重于完善戒烟指南和探索新的烟草替代品。
{"title":"Smoking-related complications in foot and ankle surgery: a systematic review.","authors":"S Pour Jafar, R Garibaldi, A Seidel, S Soares","doi":"10.26355/eurrev_202412_37003","DOIUrl":"https://doi.org/10.26355/eurrev_202412_37003","url":null,"abstract":"<p><strong>Objective: </strong>The detrimental effects of cigarette smoking on overall health are well-documented, with nicotine and carbon monoxide contributing to peripheral vasoconstriction and impaired oxygen delivery to tissues. This study reviews the impact of smoking on wound and bone healing, specifically in foot and ankle surgery, given its significant role as a modifiable risk factor for complications in orthopedic procedures.</p><p><strong>Materials and methods: </strong>A systematic literature review was conducted in May 2024 following PRISMA guidelines. An electronic search of PubMed was performed using keywords related to smoking and wound complications in foot and ankle surgery. Inclusion criteria were studies published in English from 1993 to May 2024 focusing on orthopedic procedures. After screening 28 studies, six relevant articles were selected, comprising literature reviews, retrospective studies, and comparative series.</p><p><strong>Results: </strong>The review highlights that smoking, including smokeless tobacco, significantly increases the risk of complications in foot and ankle surgeries. Smokers show markedly higher rates of non-union, wound infections, and delayed bone healing compared to non-smokers. For instance, smokers exhibit a 14.8% wound infection rate and higher rates of malunion and non-union, with 14.5% vs. 6.7% in non-smokers. Elective procedures such as total ankle replacement (TAR) also show worse outcomes for smokers, including increased infection rates and poorer functional scores. Conversely, smoking's impact on amputation procedures is less pronounced, although complications remain significant in patients with comorbid conditions.</p><p><strong>Conclusions: </strong>This review underscores the severe impact of smoking on surgical outcomes in foot and ankle procedures. Smoking cessation before surgery has demonstrated substantial benefits, including reduced infection rates and improved healing. Preoperative counseling and smoking cessation programs are crucial for optimizing patient outcomes, and a multidisciplinary approach should be considered to enhance therapeutic strategies. Future studies should focus on refining smoking cessation guidelines and exploring new tobacco alternatives.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 24","pages":"4691-4700"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of machine learning algorithms and computational structural validation of CYP2D6 in predicting the therapeutic response to tamoxifen in breast cancer. 机器学习算法的评估和CYP2D6的计算结构验证预测乳腺癌对他莫昔芬的治疗反应。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_37005
K Sridharan, K Sekaran, C George Priya Doss

Objective: CYP2D6 plays a critical role in metabolizing tamoxifen into its active metabolite, endoxifen, which is crucial for its therapeutic effect in estrogen receptor-positive breast cancer. Single nucleotide polymorphisms (SNPs) in the CYP2D6 gene can affect enzyme activity and thus impact tamoxifen efficacy. This study aimed to use machine learning algorithms (MLAs) to identify significant predictors of Breast Cancer-Free Interval (BCFI) and to apply bioinformatics tools to investigate the structural and functional implications of CYP2D6 SNPs.

Patients and methods: The study utilized data from 4,974 breast cancer patients recruited by the International Tamoxifen Pharmacogenomics Consortium (ITPC), focusing on 898 patients with available BCFI data. Predictors included age, ethnicity, menopausal status, breast cancer grade, CYP2D6 genotype, and BCFI. An ensemble MLA model was developed, incorporating regression, CHAID, artificial neural networks (ANN), and classification and regression trees (CART). Bioinformatics tools, such as STRING-DB and GEPIA2, were used to analyze protein-protein interactions and survival data related to CYP2D6.

Results: The ensemble model identified age and CYP2D6 genotypes as significant predictors of BCFI. The mean prediction error for the training and testing cohorts was 13.8 and 40.2 days, respectively. Bioinformatics analysis revealed reduced CYP2D6 functional activity associated with decreased survival, and Kaplan-Meier analysis demonstrated that lower CYP2D6 expression significantly reduced survival rates.

Conclusions: This study highlights the utility of MLAs in identifying key predictors of tamoxifen response and the value of bioinformatics in understanding CYP2D6's role in breast cancer outcomes. Personalized treatment approaches based on CYP2D6 metabolizer status could enhance tamoxifen therapy effectiveness.

目的:CYP2D6在他莫昔芬代谢为其活性代谢物endoxifen的过程中起关键作用,对其治疗雌激素受体阳性乳腺癌的疗效至关重要。CYP2D6基因的单核苷酸多态性(snp)可以影响酶的活性,从而影响他莫昔芬的疗效。本研究旨在利用机器学习算法(MLAs)识别乳腺癌无癌间隔(BCFI)的重要预测因子,并应用生物信息学工具研究CYP2D6 snp的结构和功能意义。患者和方法:该研究利用了国际他莫昔芬药物基因组学联盟(ITPC)招募的4,974名乳腺癌患者的数据,重点关注898名具有BCFI数据的患者。预测因素包括年龄、种族、绝经状态、乳腺癌分级、CYP2D6基因型和BCFI。建立了一个集成了回归、CHAID、人工神经网络(ANN)和分类回归树(CART)的集成MLA模型。使用生物信息学工具,如STRING-DB和GEPIA2,分析与CYP2D6相关的蛋白-蛋白相互作用和存活数据。结果:集合模型确定年龄和CYP2D6基因型是BCFI的重要预测因子。训练组和测试组的平均预测误差分别为13.8天和40.2天。生物信息学分析显示CYP2D6功能活性降低与生存率降低相关,Kaplan-Meier分析显示CYP2D6表达降低显著降低生存率。结论:本研究强调了MLAs在确定他莫昔芬反应的关键预测因素方面的效用,以及生物信息学在了解CYP2D6在乳腺癌预后中的作用方面的价值。基于CYP2D6代谢状态的个性化治疗方法可以提高他莫昔芬的治疗效果。
{"title":"Evaluation of machine learning algorithms and computational structural validation of CYP2D6 in predicting the therapeutic response to tamoxifen in breast cancer.","authors":"K Sridharan, K Sekaran, C George Priya Doss","doi":"10.26355/eurrev_202412_37005","DOIUrl":"https://doi.org/10.26355/eurrev_202412_37005","url":null,"abstract":"<p><strong>Objective: </strong>CYP2D6 plays a critical role in metabolizing tamoxifen into its active metabolite, endoxifen, which is crucial for its therapeutic effect in estrogen receptor-positive breast cancer. Single nucleotide polymorphisms (SNPs) in the CYP2D6 gene can affect enzyme activity and thus impact tamoxifen efficacy. This study aimed to use machine learning algorithms (MLAs) to identify significant predictors of Breast Cancer-Free Interval (BCFI) and to apply bioinformatics tools to investigate the structural and functional implications of CYP2D6 SNPs.</p><p><strong>Patients and methods: </strong>The study utilized data from 4,974 breast cancer patients recruited by the International Tamoxifen Pharmacogenomics Consortium (ITPC), focusing on 898 patients with available BCFI data. Predictors included age, ethnicity, menopausal status, breast cancer grade, CYP2D6 genotype, and BCFI. An ensemble MLA model was developed, incorporating regression, CHAID, artificial neural networks (ANN), and classification and regression trees (CART). Bioinformatics tools, such as STRING-DB and GEPIA2, were used to analyze protein-protein interactions and survival data related to CYP2D6.</p><p><strong>Results: </strong>The ensemble model identified age and CYP2D6 genotypes as significant predictors of BCFI. The mean prediction error for the training and testing cohorts was 13.8 and 40.2 days, respectively. Bioinformatics analysis revealed reduced CYP2D6 functional activity associated with decreased survival, and Kaplan-Meier analysis demonstrated that lower CYP2D6 expression significantly reduced survival rates.</p><p><strong>Conclusions: </strong>This study highlights the utility of MLAs in identifying key predictors of tamoxifen response and the value of bioinformatics in understanding CYP2D6's role in breast cancer outcomes. Personalized treatment approaches based on CYP2D6 metabolizer status could enhance tamoxifen therapy effectiveness.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 24","pages":"4712-4722"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term blood pressure control assessment using time spent in therapeutic range among Saudi patients. 在沙特患者中使用治疗范围内花费的时间进行长期血压控制评估。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_36976
M A Alshabeeb, R Alajlan, S Abohelaika, F A Alherz, A A Alqurain, F A Alomar

Objective: Time in therapeutic range (TTR) is a new approach to monitoring blood pressure (BP), providing a more accurate picture over time compared to the standard single BP measurement during a clinic visit. Currently, no study from Saudi Arabia has explored the use of TTR in assessing BP control and its related factors. Thus, we aimed to investigate them in this study.

Patients and methods: Participants aged ≥ 18 years with at least three BP measurements from January 2016 to December 2020 were enrolled. Patient data were collected, including the date of hypertension (HTN) diagnosis, comorbidities, medication history, and laboratory test results. TTR values were calculated, and descriptive statistical analysis was applied to assess the differences between patients with TTR ≥ 50% and those with TTR < 50%. The Poisson regression model was used to describe the associations between patient characteristics and TTR values.

Results: 30,694 patients were included, with 74% identified as having TTR < 50%. Female gender, concomitant diabetes mellitus, or cardiovascular diseases were significantly associated with TTR ≥ 50% (p < 0.02). Conversely, increasing age, body mass index, years with HTN, or hyperlipidemia were associated with TTR < 50% (p < 0.001).

Conclusions: According to the 2017 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines, about three-quarters of the patients presented with TTR < 50% among the screened Saudi cohort. The results of this study may raise concerns about clinicians' adherence to the updated HTN management guidelines and patients' compliance with their treatment plans. This underscores the urgent need to improve HTN management and TTR attainment among Saudi patients.

目的:治疗范围内时间(TTR)是一种监测血压(BP)的新方法,与临床访问期间的标准单次血压测量相比,它提供了更准确的随时间变化的图像。目前,沙特阿拉伯尚未有研究探讨使用TTR评估BP控制及其相关因素。因此,我们在本研究中旨在调查他们。患者和方法:在2016年1月至2020年12月期间,年龄≥18岁且至少进行过三次血压测量的参与者被纳入研究。收集患者资料,包括高血压(HTN)诊断日期、合并症、用药史和实验室检查结果。计算TTR值,并采用描述性统计分析评估TTR≥50%与TTR < 50%患者的差异。泊松回归模型用于描述患者特征与TTR值之间的关系。结果:纳入30,694例患者,其中74%确定为TTR < 50%。女性、合并糖尿病或心血管疾病与TTR≥50%显著相关(p < 0.02)。相反,年龄、体重指数、HTN发病年限或高脂血症的增加与TTR < 50%相关(p < 0.001)。结论:根据2017年美国心脏病学会和美国心脏协会(ACC/AHA)指南,在筛查的沙特队列中,约有四分之三的患者的TTR < 50%。本研究的结果可能会引起临床医生对最新HTN管理指南的依从性和患者对其治疗计划的依从性的关注。这强调了改善沙特患者HTN管理和TTR实现的迫切需要。
{"title":"Long-term blood pressure control assessment using time spent in therapeutic range among Saudi patients.","authors":"M A Alshabeeb, R Alajlan, S Abohelaika, F A Alherz, A A Alqurain, F A Alomar","doi":"10.26355/eurrev_202412_36976","DOIUrl":"https://doi.org/10.26355/eurrev_202412_36976","url":null,"abstract":"<p><strong>Objective: </strong>Time in therapeutic range (TTR) is a new approach to monitoring blood pressure (BP), providing a more accurate picture over time compared to the standard single BP measurement during a clinic visit. Currently, no study from Saudi Arabia has explored the use of TTR in assessing BP control and its related factors. Thus, we aimed to investigate them in this study.</p><p><strong>Patients and methods: </strong>Participants aged ≥ 18 years with at least three BP measurements from January 2016 to December 2020 were enrolled. Patient data were collected, including the date of hypertension (HTN) diagnosis, comorbidities, medication history, and laboratory test results. TTR values were calculated, and descriptive statistical analysis was applied to assess the differences between patients with TTR ≥ 50% and those with TTR < 50%. The Poisson regression model was used to describe the associations between patient characteristics and TTR values.</p><p><strong>Results: </strong>30,694 patients were included, with 74% identified as having TTR < 50%. Female gender, concomitant diabetes mellitus, or cardiovascular diseases were significantly associated with TTR ≥ 50% (p < 0.02). Conversely, increasing age, body mass index, years with HTN, or hyperlipidemia were associated with TTR < 50% (p < 0.001).</p><p><strong>Conclusions: </strong>According to the 2017 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines, about three-quarters of the patients presented with TTR < 50% among the screened Saudi cohort. The results of this study may raise concerns about clinicians' adherence to the updated HTN management guidelines and patients' compliance with their treatment plans. This underscores the urgent need to improve HTN management and TTR attainment among Saudi patients.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4656-4665"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9. 撤稿说明:MiR-5692a通过MMP9促进肝细胞癌的侵袭和转移。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_36973
S-J Sun, N Wang, Z-W Sun, J Chen, H-W Cui

The article "MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9" by S.-J. Sun, N. Wang, Z.-W. Sun, J. Chen, H.-W. Cui, published Eur Rev Med Pharmacol Sci 2018; 22 (15): 4869-4878-DOI: 10.26355/eurrev_201808_15623-PMID: 30070322 has been retracted by the Editor in Chief. Due to concerns raised by online readers regarding a set of articles published by different publishers sharing similarities in Kaplan-Meier survival plots, correlation plots, and overlapping images from wound-healing and transwell assays, the Editor-in-Chief has initiated an investigation to evaluate the validity of the results and potential figure manipulation. The journal's investigation revealed duplications between panels A of Figure 4 and panel B of Figure 5. Also, splicing was detected in panel A of Figure 4. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15623.

S.-J.Sun、N. Wang、Z.-W. Sun、J. Chen、H.-W. Sun发表的文章 "MiR-5692a通过MMP9促进肝细胞癌的侵袭和转移"。Sun, J. Chen, H.-W.Cui, published Eur Rev Med Pharmacol Sci 2018; 22 (15):4869-4878-DOI: 10.26355/eurrev_201808_15623-PMID: 30070322 已被主编撤回。由于在线读者对不同出版商发表的一组文章中存在相似的 Kaplan-Meier 生存图、相关图以及重叠的伤口愈合和转孔试验图像表示担忧,主编已启动调查,以评估结果的有效性和潜在的数字篡改。期刊调查发现,图 4 的面板 A 和图 5 的面板 B 之间存在重复。此外,在图 4 的面板 A 中还发现了拼接。作者已被告知期刊的调查情况,但一直没有回应,也没有提供研究的原始数据。因此,主编不相信所提供的结果,决定撤回这篇文章。这篇文章已被撤回。出版商对此造成的不便深表歉意。https://www.europeanreview.org/article/15623。
{"title":"Retraction Note: MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.","authors":"S-J Sun, N Wang, Z-W Sun, J Chen, H-W Cui","doi":"10.26355/eurrev_202412_36973","DOIUrl":"https://doi.org/10.26355/eurrev_202412_36973","url":null,"abstract":"<p><p>The article \"MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9\" by S.-J. Sun, N. Wang, Z.-W. Sun, J. Chen, H.-W. Cui, published Eur Rev Med Pharmacol Sci 2018; 22 (15): 4869-4878-DOI: 10.26355/eurrev_201808_15623-PMID: 30070322 has been retracted by the Editor in Chief. Due to concerns raised by online readers regarding a set of articles published by different publishers sharing similarities in Kaplan-Meier survival plots, correlation plots, and overlapping images from wound-healing and transwell assays, the Editor-in-Chief has initiated an investigation to evaluate the validity of the results and potential figure manipulation. The journal's investigation revealed duplications between panels A of Figure 4 and panel B of Figure 5. Also, splicing was detected in panel A of Figure 4. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15623.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4644"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer. 撤稿说明:SIRT1 诱导的 HMGB1 表达和乙酰化在卵巢癌的迁移、侵袭和血管生成中的功能作用。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_36974
W Jiang, P Jiang, R Yang, D-F Liu

The article "Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer" by W. Jiang, P. Jiang, R. Yang, D.-F. Liu, published in Eur Rev Med Pharmacol Sci 2018; 22 (14): 4431-4439-DOI: 10.26355/eurrev_201807_15494-PMID: 30058682 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/B4079372E27EE32646DBD24D98E7DA), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation revealed duplications between panels A and B of Figure 1, between Figure 3 and a previously published article (link: https://doi.org/10.1371/journal.pone.0140918), and image duplication and rotation within panel Normal Control of Figure 6C. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief has decided to retract the manuscript. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15494.

《sirt1诱导的HMGB1表达和乙酰化在卵巢癌迁移、侵袭和血管生成中的功能作用》蒋伟,蒋平,杨瑞华,d.f。Liu,发表于Eur Rev Med Pharmacol Sci 2018;22 (14): 4431-4439-DOI: 10.26355/eurrev_201807_15494-PMID: 30058682已被主编撤回。在PubPeer(链接:https://pubpeer.com/publications/B4079372E27EE32646DBD24D98E7DA)上引起了一些关注之后,总编辑已经开始进行调查,以评估结果的有效性以及可能的数字操纵。该杂志的调查发现,图1的面板A和B之间、图3和之前发表的一篇文章(链接:https://doi.org/10.1371/journal.pone.0140918)之间存在重复,图6C的面板Normal Control中存在图像复制和旋转。作者已经被告知该杂志的调查,但仍然没有回应,也没有提供研究的原始数据。因此,总编辑决定撤回手稿。这篇文章已被撤回。对于由此造成的任何不便,出版商深表歉意。https://www.europeanreview.org/article/15494。
{"title":"Retraction Note: Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer.","authors":"W Jiang, P Jiang, R Yang, D-F Liu","doi":"10.26355/eurrev_202412_36974","DOIUrl":"https://doi.org/10.26355/eurrev_202412_36974","url":null,"abstract":"<p><p>The article \"Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer\" by W. Jiang, P. Jiang, R. Yang, D.-F. Liu, published in Eur Rev Med Pharmacol Sci 2018; 22 (14): 4431-4439-DOI: 10.26355/eurrev_201807_15494-PMID: 30058682 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/B4079372E27EE32646DBD24D98E7DA), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation revealed duplications between panels A and B of Figure 1, between Figure 3 and a previously published article (link: https://doi.org/10.1371/journal.pone.0140918), and image duplication and rotation within panel Normal Control of Figure 6C. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief has decided to retract the manuscript. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15494.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4645"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual analogue scale foot and ankle vs. short-form 36 quality of life scores: artificial intelligence using machine learning analysis with an external validation. 视觉模拟量表足踝评分与短表 36 生活质量评分:人工智能机器学习分析与外部验证。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_36977
C Angthong, P Rajbhandari, W Angthong

Objective: We aimed to utilize artificial intelligence (AI) via machine learning (ML) to analyze the relationship between visual analogue scale foot and ankle (VASFA) and short-form 36 (SF-36) quality of life scores and determine AI's performance over the aforementioned analysis.

Materials and methods: We collected data from our registry of 819 data units or rows of datasets of foot and ankle patients with VASFA, SF-36 scores, and other demographic data. They were prepared and verified to be a proper input for building ML models using a web-based algorithm platform. After the first ML model was developed using random forest regression, the SF-36 percentage value was set as an endpoint. We developed a second ML model to evaluate it against the current algorithm. This new model employed a gradient-boosting regressor, where we omitted a key parameter, SF_Total, to correct the overfitting. We performed an external validation based on an unseen dataset from 42 data units of patients.

Results: Internal validity showed an excellent relationship among the VASFA, SF-36 total score, and overall SF-36 percent values at a correlation coefficient (R2 score) of 1.000 based on the random forest regression model of ML (first model: 28XJ). The VASFA percent value of the total score (0=worst; 100=best) demonstrated the dynamic changes in the three zones of the score levels; these were unsatisfactory: ≤ 57.25; borderline: 57.26-80.99; satisfactory: ≥ 81 and could impact the levels of overall SF-36 percent value. A second ML model (model FK13) showed an R2 score of 0.977, which was a great performance. External validation showed no significant difference between the predicted and actual values, with a two-tailed p-value of 0.2136.

Conclusions: Our ML models predicted excellent relationships among VASFA, with or without SF-36 total score and overall SF-36 percentage values, with evidence from external validation.

目的:我们旨在通过机器学习(ML)利用人工智能(AI)分析足踝视觉模拟量表(VASFA)与短表 36(SF-36)生活质量评分之间的关系,并确定人工智能在上述分析中的表现:我们从足踝患者的 819 个数据单元或数据集行中收集了 VASFA、SF-36 评分和其他人口统计学数据。这些数据经过准备和验证,可作为使用基于网络的算法平台建立 ML 模型的适当输入。使用随机森林回归法建立第一个 ML 模型后,SF-36 百分比值被设定为终点。我们开发了第二个 ML 模型,以对当前算法进行评估。这个新模型采用了梯度提升回归法,我们省略了一个关键参数 SF_Total,以纠正过度拟合。我们根据来自 42 个患者数据单元的未见数据集进行了外部验证:基于 ML 随机森林回归模型(第一模型:28XJ)的内部有效性表明,VASFA、SF-36 总分和 SF-36 百分比总值之间的相关系数(R2 值)为 1.000。总分的 VASFA 百分比值(0=最差;100=最好)显示了得分水平三个区域的动态变化;这三个区域分别是不满意:≤ 57.25;边缘:57.26-80.99;满意:≥ 81,并可能影响 SF-36 百分比值的整体水平。第二个 ML 模型(模型 FK13)的 R2 值为 0.977,表现出色。外部验证显示,预测值和实际值之间没有明显差异,双尾 p 值为 0.2136:我们的 ML 模型可以预测 VASFA 与 SF-36 总分或 SF-36 百分比值之间的良好关系,外部验证也证明了这一点。
{"title":"Visual analogue scale foot and ankle vs. short-form 36 quality of life scores: artificial intelligence using machine learning analysis with an external validation.","authors":"C Angthong, P Rajbhandari, W Angthong","doi":"10.26355/eurrev_202412_36977","DOIUrl":"https://doi.org/10.26355/eurrev_202412_36977","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to utilize artificial intelligence (AI) via machine learning (ML) to analyze the relationship between visual analogue scale foot and ankle (VASFA) and short-form 36 (SF-36) quality of life scores and determine AI's performance over the aforementioned analysis.</p><p><strong>Materials and methods: </strong>We collected data from our registry of 819 data units or rows of datasets of foot and ankle patients with VASFA, SF-36 scores, and other demographic data. They were prepared and verified to be a proper input for building ML models using a web-based algorithm platform. After the first ML model was developed using random forest regression, the SF-36 percentage value was set as an endpoint. We developed a second ML model to evaluate it against the current algorithm. This new model employed a gradient-boosting regressor, where we omitted a key parameter, SF_Total, to correct the overfitting. We performed an external validation based on an unseen dataset from 42 data units of patients.</p><p><strong>Results: </strong>Internal validity showed an excellent relationship among the VASFA, SF-36 total score, and overall SF-36 percent values at a correlation coefficient (R2 score) of 1.000 based on the random forest regression model of ML (first model: 28XJ). The VASFA percent value of the total score (0=worst; 100=best) demonstrated the dynamic changes in the three zones of the score levels; these were unsatisfactory: ≤ 57.25; borderline: 57.26-80.99; satisfactory: ≥ 81 and could impact the levels of overall SF-36 percent value. A second ML model (model FK13) showed an R2 score of 0.977, which was a great performance. External validation showed no significant difference between the predicted and actual values, with a two-tailed p-value of 0.2136.</p><p><strong>Conclusions: </strong>Our ML models predicted excellent relationships among VASFA, with or without SF-36 total score and overall SF-36 percentage values, with evidence from external validation.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4666-4670"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review. 泌尿微生物组在男性良性前列腺增生(BPH)中的作用及其使用益生菌补充剂的管理:叙述性回顾。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-12-01 DOI: 10.26355/eurrev_202412_36978
N Schifano, P Capogrosso, S Baldini, A Villano, G Antonini, F Deho'

Benign prostatic hyperplasia (BPH) is highly prevalent and associated with a significant impact on individuals' well-being. Initial management involves various medications, but their benefits can be limited by side effects, particularly concerning young people. In this context, novel and better-tolerated therapeutic strategies have been proposed, thus including the modulation of the gut microbiome through probiotic ingestion. We aimed to examine the available evidence linking the urinary microbiome to lower urinary tract symptoms (LUTS) and to evaluate the possible usefulness of probiotic supplementation as a novel treatment option for LUTS/BPH. A narrative review design was preferred to fulfill our purpose. The search strategy included a range of terms, e.g., "microbiome," "microbiota," "urobiome," AND/OR "probiotics" AND "benign prostatic hyperplasia," "benign prostatic enlargement," "lower urinary tract symptoms." A range of studies aimed to investigate the possible impact of urinary microbiome on BPH. Gut and/or urinary dysbiosis can alter the gut permeability and initiate/maintain inflammatory and oxidative processes in the prostate, which may contribute to the cell-hyper-proliferation leading to BPH. The modulation of the urinary and/or gut microbiome through probiotic supplementation seems to provide levels of clinical effectiveness in the management of BPH. Although different probiotics have been tested, a combination of B. Longum and F. Psychaerophilum seems to be particularly promising due to their capability of modulating both the inflammatory pathway and the intestinal barrier permeability. Gut and/or urinary microbiome dysbiosis is most likely contributing to the BPH pathogenesis. Even though only scarce evidence on the potential usefulness of probiotic supplementation in the management of BPH is currently available, the available studies seem to provide encouraging results. Further prospective trials are warranted in order to confirm these findings and to clarify which probiotic strains are more suitable for supplementation in this setting.

良性前列腺增生(BPH)是非常普遍的,并与个人的福祉显著影响。最初的治疗包括各种药物,但它们的益处可能受到副作用的限制,特别是对年轻人。在这种情况下,新的和更好耐受的治疗策略被提出,因此包括通过益生菌摄入调节肠道微生物组。我们的目的是检查尿微生物组与下尿路症状(LUTS)联系的现有证据,并评估益生菌补充作为LUTS/BPH的新治疗选择的可能有用性。叙述性回顾设计更适合我们的目的。搜索策略包括一系列术语,例如“微生物组”、“微生物群”、“泌尿组”和/或“益生菌”和“良性前列腺增生”、“良性前列腺增大”、“下尿路症状”。一系列的研究旨在调查泌尿微生物群对前列腺增生的可能影响。肠道和/或泌尿系统失调可以改变肠道通透性,启动/维持前列腺的炎症和氧化过程,这可能有助于细胞过度增殖,导致前列腺增生。通过补充益生菌调节尿液和/或肠道微生物群似乎在BPH管理中提供了临床有效性水平。虽然已经测试了不同的益生菌,但长芽胞杆菌和嗜气荚膜菌的组合似乎特别有希望,因为它们具有调节炎症途径和肠屏障通透性的能力。肠道和/或泌尿系统微生物群失调最有可能导致前列腺增生。尽管目前只有很少的证据表明益生菌补充剂在BPH管理中的潜在作用,但现有的研究似乎提供了令人鼓舞的结果。进一步的前瞻性试验是必要的,以证实这些发现,并澄清哪些益生菌菌株更适合在这种情况下补充。
{"title":"The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.","authors":"N Schifano, P Capogrosso, S Baldini, A Villano, G Antonini, F Deho'","doi":"10.26355/eurrev_202412_36978","DOIUrl":"https://doi.org/10.26355/eurrev_202412_36978","url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is highly prevalent and associated with a significant impact on individuals' well-being. Initial management involves various medications, but their benefits can be limited by side effects, particularly concerning young people. In this context, novel and better-tolerated therapeutic strategies have been proposed, thus including the modulation of the gut microbiome through probiotic ingestion. We aimed to examine the available evidence linking the urinary microbiome to lower urinary tract symptoms (LUTS) and to evaluate the possible usefulness of probiotic supplementation as a novel treatment option for LUTS/BPH. A narrative review design was preferred to fulfill our purpose. The search strategy included a range of terms, e.g., \"microbiome,\" \"microbiota,\" \"urobiome,\" AND/OR \"probiotics\" AND \"benign prostatic hyperplasia,\" \"benign prostatic enlargement,\" \"lower urinary tract symptoms.\" A range of studies aimed to investigate the possible impact of urinary microbiome on BPH. Gut and/or urinary dysbiosis can alter the gut permeability and initiate/maintain inflammatory and oxidative processes in the prostate, which may contribute to the cell-hyper-proliferation leading to BPH. The modulation of the urinary and/or gut microbiome through probiotic supplementation seems to provide levels of clinical effectiveness in the management of BPH. Although different probiotics have been tested, a combination of B. Longum and F. Psychaerophilum seems to be particularly promising due to their capability of modulating both the inflammatory pathway and the intestinal barrier permeability. Gut and/or urinary microbiome dysbiosis is most likely contributing to the BPH pathogenesis. Even though only scarce evidence on the potential usefulness of probiotic supplementation in the management of BPH is currently available, the available studies seem to provide encouraging results. Further prospective trials are warranted in order to confirm these findings and to clarify which probiotic strains are more suitable for supplementation in this setting.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4671-4679"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diuretic activity of ethanolic extract and fraction enriched in saponins from Solanum sisymbriifolium Lam. root in rats. 茄属植物根的乙醇提取物和富含皂甙的馏分对大鼠的利尿活性
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36911
W J Arrúa, J G Duarte, M C Hellión-Ibarrola, D A Ibarrola

Objective: Solanum sisymbriifolium Lam. is a native perennial plant with chemical characteristics of therapeutic importance. In Paraguayan traditional medicine, it is attributed to antihypertensive and diuretic activities. For this reason, the objective of the study was to evaluate the effect of acute oral administration of the ethanolic extract and fraction enriched in saponins obtained from the root of S. sisymbriifolium on the diuresis profile of rats.

Materials and methods: Male Wistar rats were used, randomly distributed in 6 groups to evaluate the diuretic activity. The control group received distilled water; the diuretic group was treated with 20 mg/kg of furosemide. Two groups were treated with 50 and 100 mg/kg of the ethanolic extract of S. sisymbriifolium, and two other groups were treated with 1 and 10 mg/kg with the fraction enriched in saponins. The animals were placed in individual metabolic cages for a period of 24 h. Urine volume was determined at 5 and 24 h, and urinary electrolytes, pH, and glomerular filtration rate at 24 h.

Results: The findings indicated that both doses of the ethanolic extract and the saponin-enriched fraction significantly increased diuresis after 24 hours of treatment. Urinary pH was not affected. A significant increase in the urinary excretion of Na+ and Cl- was observed without affecting the elimination of K+ with both doses of the extracts. In addition, a significant increase in GFR was evidenced.

Conclusions: Both ethanolic extract and saponins enriched fraction, presented natriuretic and saluretic effects with a possible mechanism of action mediated, at least partially, by the inhibition of carbonic anhydrase. Furthermore, it was possible to demonstrate the participation of the COX/PG pathway in the diuretic mechanism of the extracts in male rats.

目的:Solanum sisymbriifolium Lam.是一种本地多年生植物,其化学特性具有重要的治疗作用。在巴拉圭传统医学中,它具有降压和利尿作用。因此,本研究旨在评估急性口服 S. sisymbriifolium 根部乙醇提取物和富含皂苷的馏分对大鼠利尿特征的影响:雄性 Wistar 大鼠随机分为 6 组,以评估其利尿活性。对照组饮用蒸馏水;利尿剂组服用 20 毫克/千克的呋塞米。两组分别接受每公斤 50 毫克和 100 毫克的菊苣皂乙醇提取物,另外两组分别接受每公斤 1 毫克和 10 毫克的富含皂苷的提取物。将动物置于单独的代谢笼中 24 小时,测定 5 和 24 小时的尿量以及 24 小时的尿电解质、pH 值和肾小球滤过率:结果:研究结果表明,乙醇提取物和皂苷富集部分的两种剂量都能在治疗 24 小时后显著增加利尿作用。尿液 pH 值未受影响。两种剂量的提取物都能明显增加尿液中 Na+ 和 Cl- 的排泄,而不影响 K+ 的排出。此外,肾小球滤过率也明显增加:结论:乙醇提取物和皂苷富集部分都具有利钠和利盐作用,其作用机制可能至少部分是通过抑制碳酸酐酶。此外,有可能证明 COX/PG 途径参与了雄性大鼠提取物的利尿机制。
{"title":"Diuretic activity of ethanolic extract and fraction enriched in saponins from Solanum sisymbriifolium Lam. root in rats.","authors":"W J Arrúa, J G Duarte, M C Hellión-Ibarrola, D A Ibarrola","doi":"10.26355/eurrev_202411_36911","DOIUrl":"10.26355/eurrev_202411_36911","url":null,"abstract":"<p><strong>Objective: </strong>Solanum sisymbriifolium Lam. is a native perennial plant with chemical characteristics of therapeutic importance. In Paraguayan traditional medicine, it is attributed to antihypertensive and diuretic activities. For this reason, the objective of the study was to evaluate the effect of acute oral administration of the ethanolic extract and fraction enriched in saponins obtained from the root of S. sisymbriifolium on the diuresis profile of rats.</p><p><strong>Materials and methods: </strong>Male Wistar rats were used, randomly distributed in 6 groups to evaluate the diuretic activity. The control group received distilled water; the diuretic group was treated with 20 mg/kg of furosemide. Two groups were treated with 50 and 100 mg/kg of the ethanolic extract of S. sisymbriifolium, and two other groups were treated with 1 and 10 mg/kg with the fraction enriched in saponins. The animals were placed in individual metabolic cages for a period of 24 h. Urine volume was determined at 5 and 24 h, and urinary electrolytes, pH, and glomerular filtration rate at 24 h.</p><p><strong>Results: </strong>The findings indicated that both doses of the ethanolic extract and the saponin-enriched fraction significantly increased diuresis after 24 hours of treatment. Urinary pH was not affected. A significant increase in the urinary excretion of Na+ and Cl- was observed without affecting the elimination of K+ with both doses of the extracts. In addition, a significant increase in GFR was evidenced.</p><p><strong>Conclusions: </strong>Both ethanolic extract and saponins enriched fraction, presented natriuretic and saluretic effects with a possible mechanism of action mediated, at least partially, by the inhibition of carbonic anhydrase. Furthermore, it was possible to demonstrate the participation of the COX/PG pathway in the diuretic mechanism of the extracts in male rats.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4526-4535"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European review for medical and pharmacological sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1